IMGN ImmunoGen Inc.

6.42
+0.23  (4%)
Previous Close 6.19
Open 6.28
Price To book -4.79
Market Cap 827509559
Shares 128,895,570
Volume 3,515,269
Short Ratio 3.30
Av. Daily Volume 3,879,430

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved Feb 22 2013 - under priority review
Kadcyla
2nd-line HER2+ Metastatic Breast Cancer
Phase 1b safety data presented at ASCO June 3, 2017. Abstract 5553.
Mirvetuximab soravtansine - FORWARD II
Ovarian cancer and relapsed endometrial cancer
Phase 2 initiated 2016
IMGN529 and rituximab
Cancer - diffuse-large B-cell lymphoma (DLBCL)
Reported April 2016 that FORWARD I, initially a Phase 2 trial, will now be a Phase 3 trial with progression-free survival as the primary endpoint. Announced January 26, 2017 that first patient has been dosed.
Mirvetuximab soravtansine - FORWARD I
Cancer - ovarian cancer and relapsed endometrial cancer
Phase 3 trial did not meet endpoints.
Kadcyla KRISTINE trial
HER2-positive breast cancer - neo-adjuvant setting
Endpoint not met - October 2015
Kadcyla GATSBY trial
Cancer - metastatic HER2+ gastric cancer
Phase 3 data due in 2019.
Kadcyla (KAITLIN)
HER2-positive breast cancer - adjuvant use
Phase 3 data due in 2018.
Kadcyla (KATHERINE).
HER2-positive breast cancer - residual invasive disease
Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy
Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial
Cancer - 1st-line HER2+ Metastatic Breast Cancer

Latest News

  1. ImmunoGen to Push Leukemia Candidate into Phase I Trial
  2. ImmunoGen Announces Investigational New Drug Application for IMGN632 for Hematological Malignancies is Active
  3. ImmunoGen Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
  4. ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : October 10, 2017
  5. Immunogen secondary offering priced below Friday's closing price
  6. ImmunoGen Announces Pricing of Public Offering of Common Stock
  7. Why ImmunoGen, Inc. Dropped Today
  8. Why ImmunoGen’s Secondary Makes Sense
  9. Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and ImmunoGen
  10. Immunogen shares fall after secondary share offering announced
  11. ImmunoGen Announces Proposed Public Offering of Common Stock
  12. Should You Be Holding ImmunoGen Inc (IMGN) Right Now?
  13. Better Buy: Exelixis, Inc. vs. Immunogen, Inc.
  14. ImmunoGen, Inc. – Value Analysis (NASDAQ:IMGN) : September 25, 2017
  15. ImmunoGen, Inc. breached its 50 day moving average in a Bearish Manner : IMGN-US : September 22, 2017
  16. ImmunoGen Inc (IMGN): Risks You Need To Consider Before Buying
  17. Is ImmunoGen Running Out of Steam, or Taking a Breather?
  18. Why Shares of ImmunoGen, Inc. Sank Today
  19. Behind Jazz’s Strategic Collaboration with ImmunoGen
  20. ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences

SEC Filings

  1. 8-K - Current report 171132712
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171129335
  3. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 171129283
  4. 8-K - Current report 171127295
  5. 424B5 - Prospectus [Rule 424(b)(5)] 171127279
  6. 424B5 - Prospectus [Rule 424(b)(5)] 171122030
  7. 8-K - Current report 171121680
  8. 8-K - Current report 171100891
  9. 8-K - Current report 171080111
  10. 8-K - Current report 171064519